23 July 2015
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today noted the confirmation by Valeant Pharmaceuticals International, Inc’s. (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb,that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for VESNEO™ (latanoprostene bunod ophthalmic solution 0.024%), an IOP lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension.
The data submitted in the NDA support VESNEO as the first nitric-oxide donating agent for ophthalmic use.